Menu

ASX Announcements (2017)

20/12/2017 Change of Substantial Holding Kroy Wen Pty Ltd
18/12/2017 Appendix 3Y – Change of Director’s Interest Notice RD
18/12/2017 Appendix 3Y – Change of Director’s Interest Notice MJ
18/12/2017 Appendix 3Y – Change of Director’s Interest Notice BS
08/12/2017 Change of Substantial Holding WG
29/11/2017 Rhinomed Completes AUD $3.6 Million Capital Raising
27/11/2017 Market Release – Trading Halt
16/11/2017 Change in Substantial Holding WG
14/11/2017 Results of General Meeting
01/11/2017 Company Announcement – Resignation of Joint Company Secretary
31/10/2017 Leading Wholesaler Phoenix Healthcare to Wholesale Mute in UK
20/10/2017 Completion of Test and Learn Program with Tier 1 US Retailer
26/09/2017 Corporate Governance Statement
26/09/2017 Rhinomed Board Charter
26/09/2017 Securities Trading Policy
29/11/2017 Successful Completion of Unmarketable Parcel Share Sale Program
29/11/2017 Rhinomed to Distribute Mute in Taiwan
19/07/2017 Leading USA Pharmacy Takes Mute into 4,300 Stores
07/07/2017 Major Expansion of Mute USA Retail Footprint
06/07/2017 Rhinomed Receives Regulatory Clearance for Taiwan
05/07/2017 Rhinomed – Less Than Marketable Parcel Sale Facility
05/07/2017 Letter to Small Shareholders
20/06/2017 Change of Address
11/05/2017 Capital Status Post Consolidation
10/05/2017 Appendix 3Y – Change of Director’s Interest Notice MJ
10/05/2017 Appendix 3Y – Change of Director’s Interest Notice EK
10/05/2017 Appendix 3Y – Change of Director’s Interest Notice BS
08/05/2017 Amcal and Guardian Core Range Mute Australia Wide
03/05/2017 Consolidation Timetable and ASX Code RNODC
28/04/2017 Results of Meeting
24/04/2017 Appendix 3Y – Change of Director’s Interest Notice RD
06/04/2017 Mute to go on Sale in Over 800 North American GNC Stores
31/03/2017 Expiry of Quoted Options (RNOOA)
29/03/2017 Notification of Consolidation Split
29/03/2017 Notice of General Meeting – To Consider All Capital Management Initiatives
29/03/2017 Notice of Change of Interests of Substantial Holder
15/03/2017 Rhinomed Receives $280k Research and Development Tax Refund
15/03/2017 Rhinomed Completes Successful Capital Raise
15/03/2017 Capital Management Initiatives
13/03/2017 Trading Halt Request
13/03/2017 Market Release – Trading Halt
08/03/2017 Mute Global Distribution Milestone Update
07/03/2017 Investor Newsletter – March 2017
30/01/2017 Working Capital Facility Established
18/01/2017 Disclosure Policy and ASX Communication Committee Charter